High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial InfarctionThe IDEAL Study: A Randomized Controlled Trial

摘要: cardiovascular death occurred in 156 (3.5%) and 143 (3.2%) the 2 groups (HR, 0.92; 95% CI, 0.73-1.15; P=.47). Death from any cause 374 (8.4%) simvastatin group 366 (8.2%) atorvastatin 0.98; 0.85-1.13; P=.81). Patients had higher rates of drug discontinuation due to nonserious adverse events; transaminase elevation resulted 43 (1.0%) vs 5 (0.1%) withdrawals (P.001). Serious myopathy rhabdomyolysis were rare both groups. Conclusions In this study patients with previous MI, intensive lowering LDL-C did not result a significant reduction primary outcome major coronary events, but reduce risk other composite secondary end points nonfatal acute MI. There no differences or all-cause mortality. MI may benefit without an increase noncardiovascular mortality serious reactions. Trial Registration ClinicalTrials.gov Identifier: NCT00159835.